News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Augurex to Present Two Posters at ADLM 2024 in Chicago
Vancouver, Canada – July 26, 2024 – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in Chicago. The event will be held from July 28 to August 1,...
Life Sciences BC Names Augurex 2024 Emerging Company of the Year
VANCOUVER, BC – Life Sciences BC (LSBC) is pleased to announce the recipients of the 26th Annual Life Sciences BC Awards presented by Farris. These awards recognize the exceptional achievements of individuals, companies, and organizations across British Columbia’s...
New Day Diagnostics Collaboration
Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing Spondylitis Vancouver, BC, Canada and Knoxville, TN, USA, 30 May 2024 – Augurex and New Day Diagnostics are excited to announce their...
Augurex has received $5M in funding from PacifiCan
Government of Canada invests almost $14 million to drive innovation and economic growth in Vancouver.Today, the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development on behalf of the Honourable Harjit S. Sajjan, Minister of...
Leading health publications are sharing the 14-3-3η blood test as part of the standard of care
Practical Pain Management highlights the 14-3-3η blood test The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the...
14-3-3η: How Joint Involvement “Spreads”
14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η's clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to assess...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist...
Commitment to Access, Quality and Growth through Innovation
Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3ƞ) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives...
New Testing And Treatment Improves Outlook For Those With Rheumatoid Arthritis
PREVENTION AND TREATMENT If you have been experiencing a prolonged period of pain, tenderness and stiffness around your joints, you should get to a doctor — and make it fast. Please read the full article on the personalhealthnews.ca website here...
JOINTstat™ – Transforming RA Patient Management
LifeLabs Medical Laboratory Services, the country's largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage...
LifeLabs Launches Arthritis Blood Test JOINTstat™ (14-3-3eta) in Canada
TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2015) - LifeLabs Medical Laboratory Services ("LifeLabs") announced today the launch of JOINTstat™, a diagnostic blood test for rheumatoid arthritis. The JOINTstat™ blood test is the first test...
New Studies Expand the Large Body of Data on the Important Role of an Arthritis Protein; 14-3-3eta Blood Test
Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world's...
NRC and Augurex collaborate to improve treatments for rheumatoid arthritis
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
Arthritis Blood Test: 14-3-3eta Ground-Breaking Data
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World’s Premier Arthritis Conference
Vancouver, BC – October 25, 2013 - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking...
Blood Marker Can Help Diagnose Rheumatoid Arthritis; New Data at the 2012 Annual Meeting of the American College of Rheumatology
International arthritis investigators this week at the 2012 Annual Meeting of the American College of Rheumatology held in Washington, DC presented data related to the 14-3-3η protein and its auto-antibodies, a promising set of new blood-based markers from Augurex,...
Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3η as a Testing Service in the U.S.
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3η...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact